- Home
- LGVN vs AKTX Comparison
LGVN vs AKTX Comparison
Compare LGVN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- AKTX
- Stock Information
- Founded
- LGVN 2014
- AKTX N/A
- Country
- LGVN United States
- AKTX United States
- Employees
- LGVN N/A
- AKTX N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- AKTX Health Care
- Exchange
- LGVN Nasdaq
- AKTX Nasdaq
- Market Cap
- LGVN 27.6M
- AKTX 29.1M
- IPO Year
- LGVN 2021
- AKTX N/A
- Fundamental
- Price
- LGVN $1.61
- AKTX $1.45
- Analyst Decision
- LGVN Strong Buy
- AKTX
- Analyst Count
- LGVN 3
- AKTX 0
- Target Price
- LGVN $8.67
- AKTX N/A
- AVG Volume (30 Days)
- LGVN 118.8K
- AKTX 28.2K
- Earning Date
- LGVN 05-13-2025
- AKTX 04-16-2025
- Dividend Yield
- LGVN N/A
- AKTX N/A
- EPS Growth
- LGVN N/A
- AKTX N/A
- EPS
- LGVN N/A
- AKTX N/A
- Revenue
- LGVN $2,392,000.00
- AKTX N/A
- Revenue This Year
- LGVN $1.30
- AKTX N/A
- Revenue Next Year
- LGVN $19.15
- AKTX N/A
- P/E Ratio
- LGVN N/A
- AKTX N/A
- Revenue Growth
- LGVN 237.38
- AKTX N/A
- 52 Week Low
- LGVN $0.77
- AKTX $0.85
- 52 Week High
- LGVN $6.40
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- LGVN 55.99
- AKTX 64.05
- Support Level
- LGVN $1.45
- AKTX $1.03
- Resistance Level
- LGVN $1.46
- AKTX $1.58
- Average True Range (ATR)
- LGVN 0.14
- AKTX 0.16
- MACD
- LGVN 0.02
- AKTX 0.02
- Stochastic Oscillator
- LGVN 100.00
- AKTX 77.72
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).